VTGN VistaGen Therapeutics
Filed: 20 Feb 20, 7:00pm
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): February 20, 2020
VistaGen Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|(State or other jurisdiction of incorporation)||(Commission File Number)||(IRS Employer Identification Number)|
343 Allerton Ave.
South San Francisco, California 94090
(Address of principal executive offices)
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
Securities registered pursuant to Section 12(b) of the Act:
|Title of each class||Trading Symbol(s)||Name of each exchange on which registered|
|Common Stock, par value $0.001 per share||VTGN||Nasdaq Capital Market|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2)
Emerging Growth Company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐
Item 8.01. Other Events.
On February 20, 2020, VistaGen Therapeutics, Inc. (the “Company”) announced positive results from a newly published exploratory Phase 2a clinical study of PH10, the Company’s investigational first-in-class, rapid-onset synthetic neurosteroid nasal spray, for treatment of major depressive disorder. Results of the double-blind, randomized, placebo-controlled Phase 2a study have been published in the peer-reviewed British Journal of Pharmaceutical and Medical Research. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.
Item 9.01. Exhibits.
|Press Release issued by VistaGen Therapeutics, Inc., dated February 20, 2020.|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|VistaGen Therapeutics, Inc.|
|Date: February 20, 2020||By:|
/s/ Shawn K. Singh
Shawn K. Singh
Chief Executive Officer